Gilenya (Fingolimod) Copay Assistance Now & Patient Savings Programs | QuickRx

Yes, completely free. QuickRx Specialty Pharmacy provides free enrollment and support for all Gilenya (fingolimod) copay assistance programs including manufacturer copay cards and patient assistance programs. We never charge service fees for helping patients access medication savings.

What’s included at no cost:

• Application assistance for Gilenya manufacturer copay cards
• Insurance verification and benefit checks
• Prior authorization support when needed
• Foundation grant applications for multiple sclerosis treatment
• First-dose observation coordination
• Ongoing monitoring to ensure continuous savings
• Prescription coordination and specialty medication delivery

Our team’s only goal is to make Gilenya more affordable so you can focus on managing your multiple sclerosis without financial stress.

Qualification depends on your insurance type and financial situation. QuickRx helps patients across all insurance categories access appropriate assistance programs.

For commercially insured patients:

Manufacturer copay cards are available for patients with private or employer-sponsored insurance. These programs can reduce your out-of-pocket costs significantly.

For Medicare patients:

While manufacturer copay cards typically cannot be used with Medicare, foundation grants and other assistance programs may be available to help cover your Gilenya costs.

For Medicaid patients:

State Medicaid programs often cover Gilenya with minimal copays. QuickRx can help navigate coverage requirements and prior authorizations.

For uninsured patients:

Patient assistance programs may provide Gilenya at no cost or significantly reduced prices based on financial need and household income.

Call (917) 830-2525 to discuss your specific situation with a QuickRx specialist.

Savings vary based on your insurance coverage and which assistance programs you qualify for. Many commercially insured patients with Gilenya copay cards pay $0 out-of-pocket for their prescription.

Typical savings scenarios:

• With manufacturer copay card: Eligible patients may pay $0
• With foundation grants: Grants can cover remaining copays after insurance
• With patient assistance programs: Uninsured patients may receive medication at no cost

QuickRx evaluates all available programs to maximize your savings and minimize out-of-pocket costs for fingolimod.

QuickRx begins working on your Gilenya copay assistance the same day you contact us. The process moves quickly once eligibility is confirmed—many patients receive their medication within days of meeting all requirements.

The overall timeline depends on several factors, including your insurance company’s response time, prior authorization requirements, and coordination with your neurologist’s office for first-dose observation scheduling.

Our team works proactively to keep things moving and will keep you informed throughout the process. Call (917) 830-2525 to get started.

Gilenya dosing is based on age and body weight, with the medication taken once daily by mouth with or without food.

Adult dosing:

The recommended dosage of Gilenya for adults and pediatric patients 10 years and older weighing more than 40 kg is 0.5 mg orally once daily.

Pediatric dosing (ages 10 and older):

• Weighing more than 40 kg: 0.5 mg orally once daily
• Weighing 40 kg or less: 0.25 mg orally once daily

Important: Fingolimod doses higher than 0.5 mg are associated with a greater incidence of adverse reactions without additional benefit.

Always take Gilenya exactly as prescribed by your neurologist.

Gilenya (fingolimod) is a sphingosine 1-phosphate (S1P) receptor modulator approved by the FDA for treating relapsing forms of multiple sclerosis. It was the first oral disease-modifying therapy approved for MS.

How Gilenya works:

Fingolimod works by temporarily keeping certain white blood cells (lymphocytes) in lymph nodes, preventing them from reaching the central nervous system where they can cause inflammation and damage to nerve cells. This mechanism helps reduce the frequency of MS relapses and slow disability progression.

Key clinical facts:

• FDA approval date: September 21, 2010
• Dosage form: Oral capsule (0.5 mg for adults, 0.25 mg or 0.5 mg for pediatric patients based on weight)
• Administration: Once daily, with or without food
• First-dose monitoring: Required 6-hour observation period

For complete prescribing information, visit the FDA drug database.

Gilenya is FDA-approved to treat relapsing forms of multiple sclerosis (MS) in both adults and pediatric patients aged 10 years and older.

Approved indications include:

• Relapsing-remitting MS (RRMS): The most common form of MS, characterized by clearly defined relapses followed by periods of remission
• Clinically isolated syndrome (CIS): A first episode of neurologic symptoms that lasts at least 24 hours
• Active secondary progressive MS: MS that has transitioned from relapsing-remitting to a more progressive course but still has relapses

For pediatric patients, Gilenya dosing is weight-based: patients weighing 40 kg or less receive 0.25 mg daily, while those over 40 kg receive the adult dose of 0.5 mg daily.

Learn more about multiple sclerosis from the National MS Society.

Yes, generic fingolimod is available. The FDA has approved generic versions of fingolimod from multiple manufacturers.

Generic fingolimod facts:

• Generic fingolimod contains the same active ingredient as brand-name Gilenya
• Generic versions undergo FDA review to ensure bioequivalence
• May offer cost savings depending on your insurance formulary
• Available as Tascenso ODT (orally disintegrating tablet) and standard capsules

QuickRx can help you access copay assistance for both brand-name Gilenya and generic fingolimod, depending on your prescription and insurance coverage. Call (917) 830-2525 to discuss your options.

Like all medications, Gilenya can cause side effects. Most side effects are manageable, and your healthcare team will monitor you closely, especially during the first-dose observation period.

Common side effects (occurring in more than 1 in 10 patients):

• Headache
• Flu
• Diarrhea
• Back pain
• Cough
• Increased liver enzymes (ALT, AST)
• Abdominal pain
• Fatigue
• Depression
• Sinusitis
• Pain in extremities
• Dizziness

Always discuss any concerning symptoms with your neurologist. QuickRx pharmacists are also available at (917) 830-2525 to answer medication questions.

Gilenya requires a 6-hour first-dose observation period because the medication can cause temporary decreases in heart rate (bradycardia) and potential heart rhythm changes when treatment begins.

What happens during first-dose observation:

• You take your first Gilenya dose at a healthcare facility
• Heart rate and blood pressure are monitored hourly for 6 hours
• An ECG is performed before the first dose and at the end of observation
• If heart rate is lowest at hour 6, monitoring continues until heart rate increases

First-dose observation is also required if:

• Treatment is interrupted for more than 14 days during the first month
• Treatment is interrupted for more than 7 days during months 2-3
• Treatment is interrupted for more than 14 consecutive days after month 3

QuickRx coordinates first-dose observation scheduling with your neurologist’s office or an approved monitoring facility.

Patients with certain heart conditions require additional evaluation and may need extended monitoring or overnight observation when starting Gilenya.

Conditions requiring cardiology consultation:

• History of heart attack, unstable angina, or heart failure
• History of second-degree (Mobitz type II) or third-degree heart block
• Sick sinus syndrome (without a pacemaker)
• QTc interval greater than 500 milliseconds
• Treatment with Class Ia or Class III antiarrhythmic drugs

Extended monitoring (overnight) may be needed for:

• Pre-existing heart conditions listed above
• Use of certain heart medications (beta-blockers, calcium channel blockers)
• History of syncope (fainting)

Your neurologist will review your cardiac history and may consult with a cardiologist before prescribing Gilenya. QuickRx can help coordinate these evaluations.

Because Gilenya affects the immune system, vaccination status should be reviewed before starting treatment.

Vaccination recommendations:

• Varicella (chickenpox): Testing for VZV antibodies is recommended if no history of chickenpox or vaccination. If not immune, VZV vaccination should be completed at least 1 month before starting Gilenya.
• Live vaccines: Should be avoided during treatment and for 2 months after stopping Gilenya
• Inactivated vaccines: May be given during treatment, though immune response may be reduced

Important timing:

• Complete all necessary vaccinations at least 1 month before starting Gilenya
• Wait at least 2 months after stopping Gilenya before receiving live vaccines

Discuss your vaccination history with your neurologist before starting fingolimod therapy.

No, Gilenya should not be used during pregnancy. Based on animal studies, fingolimod may cause fetal harm, including an increased risk of birth defects.

Important pregnancy considerations:

• Women of childbearing potential should use effective contraception during treatment and for 2 months after stopping Gilenya
• Pregnancy testing is required before starting treatment
• If pregnancy occurs during treatment, Gilenya should be stopped immediately and the patient should inform their healthcare provider

Planning for pregnancy:

• Discuss family planning with your neurologist before starting Gilenya
• Fingolimod should be stopped at least 2 months before attempting to conceive
• MS relapses may occur after stopping treatment

For more information about MS and pregnancy, consult the National MS Society.

Proper storage helps ensure your Gilenya medication remains effective throughout your treatment.

Storage requirements:

• Temperature: Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F)
• Moisture: Protect from moisture
• Container: Keep in original container until ready to use

QuickRx delivers Gilenya in temperature-controlled packaging and provides storage instructions with each shipment. If you have any concerns about your medication’s storage or appearance, contact us at (917) 830-2525.

Call your doctor for instructions. If you miss 1 or more doses, you may need to take your next dose under medical observation in a medical setting.

First-dose observation is required again if:

• During the first 2 weeks: more than 1 day missed
• During weeks 3-4: more than 7 days missed
• After month 1: more than 14 consecutive days missed

Contact QuickRx or your neurologist if you’ve missed multiple doses. We can help determine whether re-initiation monitoring is needed and coordinate scheduling.

QuickRx Specialty Pharmacy is a nationwide specialty pharmacy licensed in all 50 states, specializing in multiple sclerosis medications including Gilenya (fingolimod).

Why patients choose QuickRx for Gilenya:

• Comprehensive copay assistance: We handle all copay card applications, patient assistance programs, and foundation grants at no charge
• First-dose coordination: We schedule and coordinate the required 6-hour observation period with your neurologist
• Clinical support: Our pharmacists specialize in MS medications and are available to answer your questions
• Insurance navigation: We handle prior authorizations and work with your insurance company directly
• Convenient delivery: Temperature-controlled home delivery with flexible scheduling
• Refill management: Proactive refill reminders and continuous benefits monitoring

Call us today at (917) 830-2525 or toll-free at (800) 496-6111 to learn how QuickRx can help make your Gilenya treatment more affordable.

Another brand name for fingolimod is Tascenso ODT, which stands for “Orally Disintegrating Tablet.” This version of fingolimod melts on the tongue and does not need to be swallowed with water, which may be helpful for patients who have difficulty swallowing capsules.

QuickRx can help you access copay assistance for both Gilenya capsules and Tascenso ODT, depending on your prescription and insurance coverage.

Gilenya and its generic fingolimod are both produced as a capsule. Tascenso ODT is available as an orally disintegrating tablet for patients who prefer not to swallow capsules.

Available formulations:

• Gilenya (brand): 0.5 mg capsule
• Fingolimod (generic): 0.25 mg and 0.5 mg capsules
• Tascenso ODT: 0.25 mg and 0.5 mg orally disintegrating tablets

Gilenya (fingolimod) should be taken orally (by mouth) with water, once daily. It can be taken with or without food.

Important administration tips:

• Take Gilenya at the same time each day
• Swallow the capsule whole—do not crush, chew, or open it
• If using Tascenso ODT, place the tablet on your tongue and let it dissolve
• Continue taking Gilenya even if you feel well

Your first dose must be taken under medical observation for at least 6 hours due to potential heart rate effects.

While it is not possible to determine what your copay cost or cash price will be for Gilenya or its generic counterpart fingolimod, calling our pharmacy team or filling out the form above will be the best way to get the fastest answers.

Your actual cost depends on several factors including your insurance plan, deductible status, and which assistance programs you qualify for. Many patients with copay cards pay $0 out-of-pocket.

We believe that high deductibles and copays shouldn’t prevent anyone from receiving the medications they need. That’s why at QuickRx, we offer help throughout the process of obtaining Gilenya copay assistance.

Our program is designed to help patients reduce their copays and out-of-pocket costs for their medication. We partner with various foundations and manufacturer assistance programs to help make a patient’s medication affordable.

Call (917) 830-2525 to discuss your options—we’re committed to finding a solution for every patient.

Here are the ways to apply for the Gilenya (fingolimod) copay assistance program:

• You can call us at (917) 830-2525
• You can also fill out our Contact Form above and someone will call you back within 1-2 business days

Our team will verify your insurance and determine which programs you’re eligible for at no cost to you.

The best place to get Gilenya prescribing information is your doctor, pharmacist, or otherwise qualified healthcare professional.

You can also find official prescribing information through:

• FDA Drug Database
• National MS Society

QuickRx pharmacists are also available to answer your medication questions at (917) 830-2525.

Gilenya is an immunosuppressant. It works by keeping immune cells trapped in your lymph nodes so they can’t reach the central nervous system (brain and spinal cord).

By modulating the immune response, Gilenya helps reduce the frequency of MS relapses and slows down the progression of the disease.

Important to understand: Gilenya will not cure MS—it will only decrease the frequency of relapse symptoms.

Gilenya is approved for the treatment of relapsing forms of MS, including:

• Relapsing-remitting MS (RRMS) — the most common form
• Active secondary progressive MS (SPMS) — in some countries
• Clinically isolated syndrome (CIS)

It is not indicated for primary progressive MS.

Your neurologist will determine if Gilenya is the right treatment option for your specific form of multiple sclerosis.